Navigation Links
Personalised Medicine: An Opportunity for Investment

LONDON, Jan. 14 /PRNewswire/ -- The pharmaceutical industry is currently facing some key challenges. The increase in drug development costs, a decrease in the number of drugs being approved, and scrutiny from regulatory authorities are forcing companies to look at alternative revenue generators. Patients themselves are also demanding more effective and safer drugs.


Pharmacogenomics therefore presents a convincing alternative to guide drug development and therapy. Pharmacogenomics deals with the influence of genetic variations on drug response in patients by correlating gene expression with a drug's efficacy. Personalised medicine is the result of individualised pharmacotherapy, which allows the formulation of drugs that offer appropriate treatment to the right person as needed.

"Recent reports of mishaps taking place due to improper drug metabolism, even when taken at optimal dose, have forced companies to consider individualised medicine more of a necessity than a mere research project," notes Frost & Sullivan ( Research Analyst Prabakar Sampath. "Every year several hundreds of patients either do not benefit from the treatment they are provided or develop adverse reactions to it. These are compelling reasons enough to pursue personalised medicine as a future directive."

Critics of personalised medicine often suggest that interest in research for a given pharmacogenomics study would decrease because it would only serve a niche market. They contend that a personalised approach would reduce new patient trials for some therapies.

However, a reduction in initial sales will be compensated by greater compliance, leading to higher product use. Frost & Sullivan believes that the commercial feasibility of personalised medicine is not what is gained or lost by moving forward, but what is at stake by not moving forward.

"The desire to meet patients' unmet medical needs, the necessity for product differentiation to gain market share and reimbursement in increasingly crowded markets in several therapeutic areas are forcing companies to invest in pharmacogenomics research," notes Sampath.

Already, genetic testing has been made easy with the increase in availability of reagents and pharmacogenetics services. Diagnostic laboratories are marketing pharmacogenomics services to physicians and in some cases, patients too.

"An ideal application of pharmacogenomics is to integrate it into clinical and nonclinical studies in order to provide value to pharmaceutical R&D by supplementing the information from these studies," says Sampath. "The goal is to provide safer and more efficient medicines, combined with diagnostics, in order to meet the needs of patients."

Pharmacogenomics provides a novel area for product differentiation, competitive advantage, and enhancement of R&D productivity. The pharmaceutical industry is learning how to best apply it in its R&D programs.

Recent initiatives, such as the formation of several pharmacogenomics-focused consortia, new regulatory guidance documents, the introduction of legislative bills and high-profile safety concerns continue to illustrate the prominent role pharmacogenomics will play in moving drug development and therapy from a population-based to an individualized paradigm.

If you are interested in more information on Frost & Sullivan's analysis of drug discovery markets, then send an e-mail to Patrick Cairns, Corporate Communications, at, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, more details will be provided.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit

    Patrick Cairns
    Corporate Communications - Europe & Africa
    P: +27 18 468 2315

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention
2. U.S. Preventive Medicine: Knowing Risk Factors & Early Detection are Best Strategies for Colon Cancer Prevention
3. Personalizing medicine: New research shows potential of targeted therapies for cancer
4. Measuring medicine: How new technologies could help doctors predict patient outcomes
5. The Changing Face of Medicine: National Medical Fellowships Annual Awards Gala Honors Three Fellows
6. Florida and California Represent Equivalent Areas of Opportunity in the Alzheimers Disease Drug Market
7. Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials'
8. Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity
9. ECPI College of Technology and Medical Careers Institute Announce Extension for South Carolina Military Scholarship Opportunity
10. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
11. HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2009 Out-of-Pocket Drug Costs
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five seconds ... critical that the first impression be positive and reflects business values. If a client ... anything or want to return. They will also share their thoughts about a business ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin ... System. Brillouin is the developer of renewable energy technologies capable of producing commercially ... (“LENR”), announced today that its WET™ and HHT™ Boiler System reactor core modules ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... is pleased to welcome Winter-Dent & Company as its newest Partner Firm. Based ... to become a client's most trusted advisor regardless of whether that client is ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the United States to support their local poison centers through donations on Tuesday, ... #GivingTuesday: calls it “a day that inspires people to collaborate in improving ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a ... of recent video interviews with some of the staff members at their recovery center. ... treatment facility, as well as some of the things that make their recovery program ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... NEWS, Va. , Nov. 24, 2015  DILON ... they have signed an agreement for DILON to distribute ... geographies across the globe. The signing of this distribution agreement ... Discovery NM750b Molecular Breast Imaging system and is considered ... to provide better healthcare solutions for clinicians and their ...
(Date:11/24/2015)... , Nov. 24, 2015 Avery Biomedical ... is pleased to announce the appointment of Anders ... Dr. Jonzon ... cardiology at Children,s Hospital, Uppsala University, Uppsala and Children,s ... 1984-1986, he was a fellow at the Cardiovascular Institute ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
Breaking Medicine Technology: